Effects of Klebsiella pneumoniae Bacteriophages on IRAK3 Knockdown/Knockout THP-1 Monocyte Cell Lines

Bryce Dylan Schubert1, Heng Ku2, Mwila Kabwe1,3

  • 1Department of Rural Clinical Sciences, La Trobe Rural Health School, La Trobe University, P.O. Box 199, Bendigo, VIC 3550, Australia.

Viruses
|November 24, 2022
PubMed

Insights

Bacteriophages offer a potential alternative to antibiotics for treating sepsis. This study found that bacteriophages targeting Klebsiella pneumoniae did not worsen the inflammatory cytokine storm in immune cells.

Area of Science:

  • Microbiology
  • Immunology
  • Virology

Background:

  • Bacterial sepsis presents a clinical challenge due to immunosuppression and cytokine storms.
  • Conventional antibiotics may exacerbate sepsis-induced cytokine storms.
  • The immunomodulatory role of bacteriophages in sepsis is not well understood.

Purpose of the Study:

  • To investigate the immunomodulatory effects of bacteriophages against Klebsiella pneumoniae in vitro.
  • To determine if bacteriophages exacerbate or mitigate inflammatory responses in immune cells.

Main Methods:

  • Isolation of two lytic bacteriophages against Klebsiella pneumoniae, including a novel jumbo bacteriophage.
  • Utilizing THP-1 monocyte cell lines with varying expression of interleukin-1 receptor associated kinase 3 (IRAK3).
  • Assessing the production of tumor necrosis factor alpha and interleukin-6 in response to bacteriophage treatment.

Main Results:

  • Bacteriophages did not induce excessive production of tumor necrosis factor alpha or interleukin-6.
  • This effect was observed across THP-1 cell lines with different IRAK3 expression levels.
  • Demonstrates a lack of pro-inflammatory cytokine storm exacerbation by these bacteriophages.

Conclusions:

  • Bacteriophages targeting K. pneumoniae do not appear to exacerbate the cytokine storm in this in vitro model.
  • These findings suggest bacteriophages may be a safer alternative for sepsis treatment compared to antibiotics.
  • Further research into bacteriophage-host immune interactions is warranted for sepsis therapy.